Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
TUSTIN, Calif., Feb. 26, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that on February 23, 2018, Paul J. Lytle notified the company of his intent to resign his position as chief financial officer, effective May 24, 2018, to spend more time with his family prior to returning to work in the drug development sector. A search for Mr. Lytle’s replacement has been initiated, and Mr. Lytle will support the transition.
“Paul has been a principal member of management for over 20 years, and his leadership was critical in the founding of the company’s contract development and manufacturing business in 2002,” said Roger Lias, Ph.D., president and chief executive officer of Avid Bioservices. “We are grateful for Paul’s many contributions to Avid and we wish him well in his future endeavors.”
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
